Aristotle

StageZero Life Sciences is a vertically integrated biotechnology company dedicated to the early detection and management of cancer and other chronic diseases through next-generation liquid biopsy diagnostics. The company's flagship product, Aristotle®, is a multi-cancer panel capable of simultaneously screening for 10 discrete cancers from a single blood sample using mRNA gene expression technology. Built on the proprietary Sentinel Principle® platform, Aristotle identifies molecular signatures indicative of early-stage disease with high sensitivity and specificity. StageZero operates a CAP-accredited and CLIA-certified reference laboratory in Richmond, Virginia, and provides a comprehensive telehealth program (AVRT™) to manage patient risk and clinical interventions. The company aims to reduce the incidence of late-stage cancer by providing accessible, non-invasive screening solutions for high-risk populations and employers.